Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Hamadani

Showing results (121-130 of 460) with videos related to

Pageof 46
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 6, 2022
Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell LymphomaMehdi Hamadani, Lei Chen, Yan Song, et al.
Future Oncology (London, England)|July 7, 2016
Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic reviewMohamed A Kharfan-Dabaja, Tea Reljic, Jessica El-Asmar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 30, 2015
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-AnalysisJessica El-Asmar, Tea Reljic, Ernesto Ayala, et al.
Blood|October 29, 2020
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?Nirav N Shah, Kwang W Ahn, Carlos Litovich, et al.
Bone Marrow Transplantation|April 14, 2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectivesPeter Dreger, Sairah Ahmed, Ali Bazarbachi, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological MalignanciesAaron Cumpston, Ryan Caddell, Alexandra Shillingburg, et al.
Clinical Hematology International|August 11, 2022
Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell LymphomasIbrahim N Muhsen, Riad El Fakih, Mehdi Hamadani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effectMehdi Hamadani, Farrukh T Awan, Patrick Elder, et al.
JAMA Oncology|March 10, 2022
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity SyndromeJoanna C Zurko, Bryon D Johnson, Emilie Aschenbrenner, et al.
Blood Advances|August 16, 2020
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapyBicky Thapa, Paolo F Caimi, Kirit M Ardeshna, et al.
Pageof 46

Showing results (121-130 of 460) with videos related to

Sort By:
Pageof 46
Clinical Lymphoma, Myeloma & Leukemia|May 6, 2022
Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell LymphomaMehdi Hamadani, Lei Chen, Yan Song, et al.
Future Oncology (London, England)|July 7, 2016
Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic reviewMohamed A Kharfan-Dabaja, Tea Reljic, Jessica El-Asmar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 30, 2015
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-AnalysisJessica El-Asmar, Tea Reljic, Ernesto Ayala, et al.
Blood|October 29, 2020
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?Nirav N Shah, Kwang W Ahn, Carlos Litovich, et al.
Bone Marrow Transplantation|April 14, 2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectivesPeter Dreger, Sairah Ahmed, Ali Bazarbachi, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological MalignanciesAaron Cumpston, Ryan Caddell, Alexandra Shillingburg, et al.
Clinical Hematology International|August 11, 2022
Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell LymphomasIbrahim N Muhsen, Riad El Fakih, Mehdi Hamadani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effectMehdi Hamadani, Farrukh T Awan, Patrick Elder, et al.
JAMA Oncology|March 10, 2022
Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity SyndromeJoanna C Zurko, Bryon D Johnson, Emilie Aschenbrenner, et al.
Blood Advances|August 16, 2020
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapyBicky Thapa, Paolo F Caimi, Kirit M Ardeshna, et al.
Pageof 46